注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Adagene Inc是一家平台驅動的臨床階段生物製藥公司,致力於改變基於抗體的新型癌症免疫療法的發現和開發。該公司主要從事癌症單克隆抗體藥物的研究、開發和生產。該公司的主要產品包括:正處於開發中的用於治療晚期實體瘤和非霍奇金淋巴瘤(NHL)的ADG106。旨在解決與現有批准的CTLA-4免疫腫瘤療法的MOA相關的毒性和功效問題,並擴大CTLA-4作為癌症治療靶標的潛力的ADG126。設計用於靶向CTLA-4的獨特保守表位的ADG116。及目前正在中國進行Ib和II期臨床試驗的靶向PD-L1的單特異性抗體ADG104。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Man Kin Tam | 45 | 2019 | CFO & Director |
Yiu Leung Cheung | 63 | 2021 | Independent Director |
Peter P. Luo | 57 | 2011 | Co- Founder, Chairman, CEO and President of R&D |
Yan Li | 48 | 2011 | Senior VP of Bioinformatics & Information Technology and Director |
Stanley R. Frankel | 64 | 2021 | Member Scientific & Strategic Advisory Board |
Steven Alan Fischkoff | 72 | 2021 | Member of Scientific & Strategic Advisory Board |
Ulf Grawunder | 58 | 2024 | Independent Director |
Heinz-Josef Lenz | 64 | 2024 | Member of Scientific & Strategic Advisory Board |
Cuong Viet Do | 58 | 2022 | Independent Director |
David R. Gandara | 76 | 2022 | Member Scientific & Strategic Advisory Board |
Yumeng Wang | 33 | 2023 | Director |
Mervyn J. Turner | 75 | 2023 | Independent Director |
Li Zhu | 74 | 2023 | Independent Director |
Robert Jay Spiegel | 75 | 2021 | Member Scientific and Strategic Advisory Board |
Aurelien Marabelle | - | 2023 | Member of Scientific & Strategic Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核